Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) FCF Margin (2022 - 2026)

bioAffinity Technologies has reported FCF Margin over the past 5 years, most recently at 239.2% for Q1 2026.

  • Quarterly FCF Margin fell 14789.0% to 239.2% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 193.11% through Mar 2026, down 11763.0% year-over-year, with the annual reading at 152.38% for FY2025, 7393.0% down from the prior year.
  • FCF Margin was 239.2% for Q1 2026 at bioAffinity Technologies, down from 160.69% in the prior quarter.
  • Over five years, FCF Margin peaked at 65.09% in Q2 2024 and troughed at 169528.23% in Q1 2023.
  • The 5-year median for FCF Margin is 190.43% (2025), against an average of 25968.94%.
  • Year-over-year, FCF Margin skyrocketed 16942902bps in 2024 and then crashed -14789bps in 2026.
  • A 5-year view of FCF Margin shows it stood at 55440.58% in 2022, then surged by 100bps to 72.42% in 2023, then decreased by -5bps to 75.97% in 2024, then crashed by -112bps to 160.69% in 2025, then tumbled by -49bps to 239.2% in 2026.
  • Per Business Quant, the three most recent readings for BIAF's FCF Margin are 239.2% (Q1 2026), 160.69% (Q4 2025), and 171.27% (Q3 2025).